Bondinell, William E; Ku, Thomas W; Neeb, Michael J;

Compounds and methods

This invention relates to substituted heteroanilide compounds which are modulators, agonists or antagonists, of the CCR5 receptior. In addition, this invention relates to the treatment and prevention of disease states mediatd by CCR5.

• Particle blast cleaning apparatus Method for positioning cable
• Mandibular repositioning device Stereoscopic endoscope system
• Activating carbonaceous electrodes Antidepressant N-substituted nicotinamide compounds
• Facsimile apparatus Shirred casing article
• Backwash system for diluting apparatus Network coupler
• Oven Thermal time-delay switch
• Mechanical split double seals Rotation-direction signal inclusion device
• Compound bow Connection apparatus
• High speed sealing machine Self-centering sheave for filaments
• Isolation circuit Softball
• Plugs for filling bony defects Heat development apparatus
• Propellant milling tool, butterfly cutter Mica-polymer micro-bits composition and process
• Capacitance adjusting circuit Bone implant
• Linear voice coil retractor Methods for diagnosing syphilis
• Firearms with target illuminators Self-cleaning perforation detector and method
• Portable folding chair Separable electrical connector assembly
• Spout master Multipin connector
• Filling and weighing system Nail corrective brace
• Polymer particles Flat panel display lighting system
• Apparatus for fabricating single crystal Gamma camera
• Portable facing and threading machine Precipitation hardening austenitic superalloys
• Compliant integrated circuit package Pesticide
• Servo control system Optical film
• Star topology local area network Torquable catheter and method
• Arm sling apparatus TRAF inhibitors
• Energy-saving closure for foundation vents Variable dimension vector quantization
• Swash plate compressor

What is claimed is:

1. A method of treating a CCR5-mediated disease state in mammals which comprises administering to a mammal in need of such treatment, an effective amount of a compound which is N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-6-chloro-2H-1-be nzopyran-3-carboxamide or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the CCR5-mediated disease state is an inflammatory disease.

3. The method of claim 1, wherein the CCR5-mediated disease state is an atopic disorder.

4. The method of claim 1, wherein the CCR5-mediated disease state is an autoimmune disorder.

5. A compound which is N-[3-[2-[Bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-6-chloro-2H-1-be nzopyran-3-carboxamide.